Circulating tumor DNA (ctDNA) has a host of benefits in treating and managing patients with early-stage disease, noted Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera.
Circulating tumor DNA (ctDNA) has a host of benefits in treating and managing patients with early-stage disease, especially in monitoring patients both in the neoadjuvant setting and during treatment, noted Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera.
Transcript
Why is ctDNA so important as an indicator in breast cancer?
So, breast cancer is a unique disease in that monitoring for response is critical for making management decisions. The ability to assess pathological CR [complete response] after completion of neoadjuvant therapy has really, really changed our approach to treating and managing patients with early-stage disease. However, the big limitation is, path CR can only be assessed after completing therapy. There's really a big need in the field for better biomarkers that can be dynamically monitored not only just in the neoadjuvant space, but also post surgically, as well as during surveillance.
In what ways does ctDNA proactively inform treatment in oncology?
The ctDNA space is multifaceted and rapidly evolving. So we really like to think about ctDNA as kind of really being a continuum of use cases. I think one really exciting and evolving use case is early cancer detection. So that's identifying cancer before histological diagnosis is made using circulating tumor DNA. On the other side of the continuum is the use case that I think many oncologists are familiar with, and that's using ctDNA to identify actionable or targetable mutations, so-called comprehensive or complete genomic profiling, typically reserved for patients in the advanced or metastatic setting.
I think really, the focus of today is really the middle of the spectrum. And that's really where Natera has focused on with their Signatera assay. And this is the minimal residual disease or molecular residual disease space, which really means identification of extremely low levels of ctDNA in the perioperative setting, both for assessment of residual disease after surgery, but also for treatment response monitoring in, for example, the neoadjuvant setting.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More